Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

Jagannadha Avasarala

doi:10.1111/bcp.16248

Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

Jagannadha Avasarala

Producción científica: Comment/debate

Idioma original	English
Páginas (desde-hasta)	3094-3096
Número de páginas	3
Publicación	British Journal of Clinical Pharmacology
Volumen	90
N.º	12
DOI	https://doi.org/10.1111/bcp.16248
Estado	Published - dic 2024

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Acceder al documento

10.1111/bcp.16248

Otros archivos y enlaces

Citar esto

@article{0e3a042e64a448748c32ca409c8e1f70,

title = "Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?",

keywords = "Anti-CD20 drugs, B cell repopulation, CD19 cell counts, COVID 19 susceptibility, dosing frequency, multiple sclerosis, vaccine response",

author = "Jagannadha Avasarala",

year = "2024",

month = dec,

doi = "10.1111/bcp.16248",

language = "English",

volume = "90",